These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9674874)

  • 1. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
    Albonico G; Querzoli P; Ferretti S; Rinaldi R; Nenci I
    Cancer Detect Prev; 1998; 22(4):313-8. PubMed ID: 9674874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters.
    Albonico G; Querzoli P; Ferretti S; Magri E; Nenci I
    Pathol Res Pract; 1996 Feb; 192(2):117-23. PubMed ID: 8692711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization.
    Jacobs TW; Pliss N; Kouria G; Schnitt SJ
    Am J Surg Pathol; 2001 Feb; 25(2):229-36. PubMed ID: 11176072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
    Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
    Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast.
    Gandhi A; Holland PA; Knox WF; Potten CS; Bundred NJ
    Br J Cancer; 1998 Sep; 78(6):788-94. PubMed ID: 9743302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T; Shousha S
    Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
    Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
    Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 protein expression in ductal carcinoma in situ (DCIS) of the breast.
    Rajan PB; Scott DJ; Perry RH; Griffith CD
    Breast Cancer Res Treat; 1997 Feb; 42(3):283-90. PubMed ID: 9065612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
    Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
    Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A
    Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. bcl-2 expression in the spectrum of preinvasive breast lesions.
    Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
    Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases.
    Sneige N; Wang J; Baker BA; Krishnamurthy S; Middleton LP
    Mod Pathol; 2002 Oct; 15(10):1044-50. PubMed ID: 12379750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast.
    Karayiannakis AJ; Bastounis EA; Chatzigianni EB; Makri GG; Alexiou D; Karamanakos P
    Eur J Surg Oncol; 1996 Dec; 22(6):578-82. PubMed ID: 9005143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.